EP1436329A4 - Anti-pdgf antibodies and methods for producing engineered antibodies - Google Patents

Anti-pdgf antibodies and methods for producing engineered antibodies

Info

Publication number
EP1436329A4
EP1436329A4 EP02775937A EP02775937A EP1436329A4 EP 1436329 A4 EP1436329 A4 EP 1436329A4 EP 02775937 A EP02775937 A EP 02775937A EP 02775937 A EP02775937 A EP 02775937A EP 1436329 A4 EP1436329 A4 EP 1436329A4
Authority
EP
European Patent Office
Prior art keywords
antibodies
anti
methods
pdgf
producing engineered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP02775937A
Other languages
German (de)
French (fr)
Other versions
EP1436329A1 (en
Inventor
Katherine S Bowdish
Shana Frederickson
Anke Kretz-Rommel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alexion Pharmaceuticals Inc
Original Assignee
Alexion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US32353701P priority Critical
Priority to US32354401P priority
Priority to US323544P priority
Priority to US323537P priority
Priority to US379994P priority
Priority to US37999402P priority
Application filed by Alexion Pharmaceuticals Inc filed Critical Alexion Pharmaceuticals Inc
Priority to PCT/US2002/030086 priority patent/WO2003025019A1/en
Publication of EP1436329A1 publication Critical patent/EP1436329A1/en
Publication of EP1436329A4 publication Critical patent/EP1436329A4/en
Application status is Withdrawn legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46Hybrid immunoglobulins
    • C07K16/461Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464Igs containing CDR-residues from one specie grafted between FR-residues from another
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
EP02775937A 2001-09-20 2002-09-20 Anti-pdgf antibodies and methods for producing engineered antibodies Withdrawn EP1436329A4 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
US32353701P true 2001-09-20 2001-09-20
US32354401P true 2001-09-20 2001-09-20
US323544P 2001-09-20
US323537P 2001-09-20
US37999402P true 2002-05-13 2002-05-13
US379994P 2002-05-13
PCT/US2002/030086 WO2003025019A1 (en) 2001-09-20 2002-09-20 Anti-pdgf antibodies and methods for producing engineered antibodies

Publications (2)

Publication Number Publication Date
EP1436329A1 EP1436329A1 (en) 2004-07-14
EP1436329A4 true EP1436329A4 (en) 2005-04-27

Family

ID=27406282

Family Applications (1)

Application Number Title Priority Date Filing Date
EP02775937A Withdrawn EP1436329A4 (en) 2001-09-20 2002-09-20 Anti-pdgf antibodies and methods for producing engineered antibodies

Country Status (4)

Country Link
EP (1) EP1436329A4 (en)
JP (1) JP2005512962A (en)
CA (1) CA2460587A1 (en)
WO (1) WO2003025019A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393648B2 (en) 2001-12-03 2008-07-01 Alexion Pharmaceuticals, Inc. Hybrid antibodies
AU2002359568B2 (en) * 2001-12-03 2008-02-21 Alexion Pharmaceuticals, Inc. Hybrid antibodies
JP2006503547A (en) * 2002-02-11 2006-02-02 アレクシオン ファーマシューティカルズ, インコーポレイテッド Immunotherapy for biological weapons defense
WO2004094473A2 (en) * 2003-04-23 2004-11-04 Medarex, Inc. Humanized antibodies to interferon alpha receptor-1 (ifnar-1)
CA2903196A1 (en) 2003-08-27 2005-03-10 Ophthotech Corporation Combination therapy for the treatment of ocular neovascular disorders
WO2005092925A2 (en) * 2004-03-24 2005-10-06 Xencor, Inc. Immunoglobulin variants outside the fc region
US7592429B2 (en) * 2005-05-03 2009-09-22 Ucb Sa Sclerostin-binding antibody
WO2009129538A2 (en) * 2008-04-18 2009-10-22 Xencor, Inc. Human equivalent monoclonal antibodies engineered from nonhuman variable regions
WO2010099139A2 (en) 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
WO2010099138A2 (en) 2009-02-27 2010-09-02 Osi Pharmaceuticals, Inc. Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US8465912B2 (en) 2009-02-27 2013-06-18 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
EP2401614A1 (en) 2009-02-27 2012-01-04 OSI Pharmaceuticals, LLC Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation
US9896730B2 (en) 2011-04-25 2018-02-20 OSI Pharmaceuticals, LLC Use of EMT gene signatures in cancer drug discovery, diagnostics, and treatment
SG10201710574UA (en) 2012-03-15 2018-02-27 Janssen Biotech Inc Human anti-cd27 antibodies, methods and uses
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
RU2014150224A (en) * 2012-06-28 2016-08-20 Молекьюлар Партнерс Аг Designed protein with ankyrin repeats, binds to the platelet-derived growth factor
JP6317748B2 (en) 2012-09-27 2018-04-25 アラーガン、インコーポレイテッドAllergan,Incorporated Biodegradable drug delivery system for protein controlled release
WO2014151725A1 (en) 2013-03-14 2014-09-25 Allergan, Inc. Composition of a sustained-release delivery and method of stabilizing proteins during fabrication process

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999024059A1 (en) * 1997-11-07 1999-05-20 Massachusetts Institute Of Technology Pdgf-mediated microvascular communication and methods of use thereof
WO1999029888A1 (en) * 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody
US6180370B1 (en) * 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817310A (en) * 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5976534A (en) * 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5700823A (en) * 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6180370B1 (en) * 1988-12-28 2001-01-30 Protein Design Labs, Inc. Humanized immunoglobulins and methods of making the same
WO1999024059A1 (en) * 1997-11-07 1999-05-20 Massachusetts Institute Of Technology Pdgf-mediated microvascular communication and methods of use thereof
WO1999029888A1 (en) * 1997-12-05 1999-06-17 The Scripps Research Institute Humanization of murine antibody

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BROECKER M ET AL: "Excessive activation of tyrosine kinases leads to inhibition of proliferation in a thyroid carcinoma cell line.", LIFE SCIENCES. 1998, vol. 63, no. 26, 1998, pages 2373 - 2386, XP002307362, ISSN: 0024-3205 *
CHUNTHARAPAI ANAN ET AL: "Characterization and humanization of a monoclonal antibody that neutralizes human leukocyte interferon: A candidate therapeutic for IDDM and SLE", CYTOKINE, vol. 15, no. 5, 7 September 2001 (2001-09-07), pages 250 - 260, XP002307361, ISSN: 1043-4666 *
See also references of WO03025019A1 *
SHIMIZU S ET AL: "In vivo and in vitro interactions between human colon carcinoma cells and hepatic stellate cells", JAPANESE JOURNAL OF CANCER RESEARCH, JAPANESE CANCER ASSOCIATION, TOKYO, JP, no. 12, December 2000 (2000-12-01), pages 1285 - 951, XP002960893, ISSN: 0910-5050 *
WU H ET AL: "Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues", JOURNAL OF MOLECULAR BIOLOGY, LONDON, GB, vol. 294, no. 1, 19 November 1999 (1999-11-19), pages 151 - 162, XP004461859, ISSN: 0022-2836 *

Also Published As

Publication number Publication date
WO2003025019A9 (en) 2004-05-06
JP2005512962A (en) 2005-05-12
CA2460587A1 (en) 2003-03-27
WO2003025019A1 (en) 2003-03-27
EP1436329A1 (en) 2004-07-14
WO2003025019A8 (en) 2004-04-01

Similar Documents

Publication Publication Date Title
TWI339209B (en) Human antibodies that bind human il-12 and methods for producing
GB2379185B (en) Implant forming method
GB2380703B (en) Implant forming method
GB2373362B (en) Micro-payment method and system
TWI329019B (en) Anti-il-6 antibodies, compositions, methods and uses
PL219013B1 (en) Taci-immunoglobulin fusion proteins
AU7922701A (en) Anti-tnf antibodies, compositions, methods and uses
IL164803D0 (en) Means and methods for the production of adenovirusvectors
PL363317A1 (en) Composite filter and method of making the same
PL374311A1 (en) Methods for purifying protein
AU2001240020A1 (en) High potency recombinant antibodies and method for producing them
IL162228D0 (en) Shaped nanocrystal particles and methods for making the same
AU2003286657A8 (en) Filters and methods of making and using the same
PL375691A1 (en) Imidazolopyridines and methods of making and using the same
HK1074197A1 (en) Micro-granulose particulates
EP1539233A4 (en) Super humanized antibodies
HRP20030087A2 (en) Anti-il-12 antibodies, compositions, methods and uses
EP1682583A4 (en) Protein complex using immunoglobulin fragment and method for the preparation thereof
AU2002306432A1 (en) Anti-interferon-alpha antibodies
HK1219487A1 (en) Cd20-specific antibodies and methods of employing same cd20
AU2002240120A1 (en) Modified antibodies and methods of use
IL149701D0 (en) Use of anti-ctla-4 antibodies
TWI473622B (en) Methods of administering anti-tnfα antibodies
AU2002365124A8 (en) Nanocrystals
IL200255A (en) Method of preparing o-desmethyl-venlafaxine

Legal Events

Date Code Title Description
AK Designated contracting states:

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR

AX Request for extension of the european patent to

Countries concerned: ALLTLVMKROSI

17P Request for examination filed

Effective date: 20040316

A4 Despatch of supplementary search report

Effective date: 20050308

17Q First examination report

Effective date: 20050808

18D Deemed to be withdrawn

Effective date: 20071219